Prospective study on the risk of hepatocellular carcinoma among hepatitis C virus-positive blood donors focusing on demographic factors, alanine aminotransferase level at donation and interaction with hepatitis B virus

International Journal of Cancer

Volumn 112, Issue 6, 2004, Pages 1075-1080

  Tanaka, Hideo ^a,c   Tsukuma, Hideaki ^a   Yamano, Hajime ^b   Oshima, Akira ^a   Shibata, Hirotoshi ^b  

^a OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^b OSAKA RED CROSS HOSPITAL   (Japan)

^c NONE   (Japan)

Author keywords

Alanine aminotransferase; Blood donor; Hepatitis B virus; Hepatitis C virus; Hepatocellular carcinoma; Interaction; Prospective study

Indexed keywords

ALANINE AMINOTRANSFERASE; CHOLESTEROL; HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY;

ADULT; AGE; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BLOOD DONOR; CANCER INCIDENCE; CANCER REGISTRY; CANCER RISK; CHOLESTEROL BLOOD LEVEL; DEMOGRAPHY; FEMALE; GENDER; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; JAPAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PASSIVE HEMAGGLUTINATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCREENING;

ADULT; AGED; ALANINE TRANSAMINASE; BLOOD DONORS; CARCINOMA, HEPATOCELLULAR; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B; HEPATITIS C; HUMANS; INCIDENCE; JAPAN; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS;

EID: 8644241083     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20507     Document Type: Article

References (45)

1. World Health Organization. Weekly epidemiological record. World Health Org 1997;46:341-4.
2. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745-50.
3. El-Serag HB, Mason AC. Risk factors for the rising rates of primary liver cancer in the United States. Arch Intern Med 2000;160:3227-30.
4. La Vecchia C, Lucchini F, Franceschi S, Negri E, Levi F. Trends in mortality from primary liver cancer in Europe. Eur J Cancer 2000;36:909-15.
5. Yoshizawa H. Hepatocellular carcinoma associated with hepatitis C virus infection in Japan: projection to other countries in the foreseeable future. Oncology 2002;62(Suppl 1):8-17.
6. Kiyosawa K, Sodeyama T, Tanaka E, Gibo Y, Yoshizawa K, Nakano Y, Furuta S, Akahane Y, Nishioka K, Purcell RH, Alter H. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 1990;12:671-5.
7. Gordon SC, Elloway RS, Long JC, Dmuchowski CF. The pathology of hepatitis C as a function of mode of transmission: blood transfusion vs. intravenous drug use. Hepatology 1993;18:1338-43.
8. Tong MJ, el-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995;332:1463-6.
9. Yano M, Kumada H, Kage M, Ikeda K, Shimamatsu K, Inoue O, Hashimoto E, Lefkowitch JH, Ludwig J, Okuda K. The long-term pathological evolution of chronic hepatitis C. Hepatology 1996;23:1334-40.
10. Niederau C, Lange S, Heintges T, Erhardt A, Buschkamp M, Hurter D, Nawrocki M, Kruska L, Hensel F, Petry W, Haussinger D. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology 1998;28:1687-95.
11. Takano S, Yokosuka O, Imazeki F, Tagawa M, Omata M. Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients. Hepatology 1995;21:650-5.
12. Di Bisceglie AM, Goodman ZD, Ishak KG, Hoofnagle JH, Melpolder JJ, Alter HJ. Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis. Hepatology 1991;14:969-74.
13. Koretz RL, Abbey H, Coleman E, Gitnick G. Non-A, non-B post-transfusion hepatitis: looking back in the second decade. Ann Intern Med 1993;119:110-5.
14. Mattsson L, Sonnerborg A, Weiland O. Outcome of acute symptomatic non-A, non-B hepatitis: a 13-year follow-up study of hepatitis C virus markers. Liver 1993;13:274-8.
15. Kenny-Walsh E, Irish Hepatology Research Group. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. N Engl J Med 1999;340:1228-33.
16. Wiese M, Berr F, Lafrenz M, Porst H, Oesen U. Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in Germany: a 20-year multicenter study. Hepatology 2000;32:91-6.
17. Rodger AJ, Roberts S, Lanigan A, Bowden S, Brown T, Crofts N. Assessment of long-term outcomes of community-acquired hepatitis C infection in a cohort with sera stored from 1971 to 1975. Hepatology 2000;32:582-7.
18. Seeff LB, Hollinger FB, Alter HJ, Wright EC, Cain CM, Buskell ZJ, Ishak KG, Iber FL, Toro D, Samanta A, Koretz RL, Perrillo RP, et al. Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: a National Heart, Lung, and Blood Institute collaborative study. Hepatology 2001;33:455-63.
19. Osella AR, Misciagna G, Guerra VM, Chiloiro M, Cuppone R, Cavallini A, Di Leo A. Hepatitis C virus (HCV) infection and liver-related mortality: a population-based cohort study in southern Italy. Int J Epidemiol 2000;29:922-7.
20. Hara M, Mori M, Hara T, Yamamoto K, Honda M, Nishizumi M. Risk of developing hepatocellular carcinoma according to the titer of antibody to hepatitis C virus. Hepatogastroenterology 2001;48:498-501.
21. Sun CA, Wu DM, Lin CC, Lu SN, You SL, Wang LY, Wu MH, Chen CJ. Incidence and cofactors of hepatitis C virus-related hepatocellular carcinoma: a prospective study of 12,008 men in Taiwan. Am J Epidemiol 2003;157:674-82.
22. Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, Galai N, Nolt K, Nelson KE, Strathdee SA, Johnson L, Laeyendecker O, Boitnott J, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000;284:450-6.
23. Ajiki W, Tsukuma H, Oshima A, Uematsu H, Takasugi Y. Japan, Osaka prefecture. In: Parkin DM, Whelam SL, Ferlay J, Teppo L, Thomas DB, eds. Cancer incidence in five continents, vol. 8. Lyon: IARC, 2003. 264-5.
24. Tanaka H, Tsukuma H, Hori Y, Nakade T, Yamano H, Kinoshita N, Oshima A, Shibata H. The risk of hepatitis C virus infection among blood donors in Osaka, Japan. J Epidemiol 1998;8:292-6.
25. Watanabe J, Matsumoto C, Fujimura K, Shimada T, Yoshizawa H, Okamoto H, Iizuka H, Tango T, Ikeda H, Endo N, Mazda T, Nojiri T, et al. Predictive value of screening tests for persistent hepatitis C virus infection evidenced by viraemia: Japanese experience. Vox Sang 1993;65:199-203.
26. Day NE. Cumulative rate and cumulative risk. In: Waterhouse J, Muir C, Shanmugaratnam K, Powell J, eds. Cancer incidence in five continents, vol. 4. Lyon: IARC, 1982. 443-5.
27. Rothman KJ. Modern epidemiology. Boston: Little, Brown, 1986. 322-6.
28. Hosmer DW, Lemeshow S. Confidence interval estimation of interaction. Epidemiology 1992;3:452-6.
29. Yoshida H, Arakawa Y, Sata M, Nishiguchi S, Yano M, Fujiyama S, Yamada G, Yokosuka O, Shiratori Y, Omata M. Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology 2002;123:483-91.
30. Kasahara A, Tanaka H, Okanoue T, Imai Y, Tsubouchi H, Yoshioka K, Kawata S, Tanaka E, Hino K, Hayashi K, Tamura S, Itoh Y, Kiyosawa K, Kakumu S, Okita K, Hayashi N. Interferon treatment improves survival in chronic hepatitis C patients showing biochemical as well as virological responses by preventing liver-related death. J Viral Hepat 2004;11:148-56.
31. Liu CJ, Chen PJ, Shau WY, Kao JH, Lai MY, Chen DS. Clinical aspects and outcomes of volunteer blood donors testing positive for hepatitis-C virus infection in Taiwan: a prospective study. Liver Int 2003;23:148-55.
32. Tanaka J, Kumada H, Ikeda K, Chayama K, Mizui M, Hino K, Katayama K, Kumagai J, Komiya Y, Miyakawa Y, Yoshizawa H. Natural histories of hepatitis C virus infection in men and women simulated by the Markov model. J Med Virol 2003;70:378-86.
33. Imai Y, Kawata S, Tamura S, Yabuuchi I, Noda S, Inada M, Maeda Y, Shirai Y, Fukuzaki T, Kaji I, Ishikawa H, Matsuda Y, et al. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Ann Intern Med 1998;129:94-9.
34. Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, We T, Sata M, Inoue O, Yano M, Tanaka M, Fujiyama S, Nishiguchi S, Kuroki T, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med 1999;131:174-81.
35. Ikeda K, Saitoh S, Arase Y, Chayama K, Suzuki Y, Kobayashi M, Tsubota A, Nakamura I, Murashima N, Kumada H, Kawanishi M. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology 1999;29:1124-30.
36. Tanaka H, Tsukuma H, Kasahara A, Hayashi N, Yoshihara H, Masuzawa M, Kanda T, Kashiwagi T, Inoue A, Kato M, Oshima A, Kinoshita Y, et al. Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients. Int J Cancer 2000;87:741-9.
37. Yu MW, Yang YC, Yang SY, Cheng SW, Liaw YF, Lin SM, Chen CJ. Hormonal markers and hepatitis B virus-related hepatocellular carcinoma risk: a nested case-control study among men. J Natl Cancer Inst 2001;93:1644-51.
38. Forns X, Ampurdanes S, Llovet JM, Aponte J, Quinto L, Martinez-Bauer E, Bruguera M, Sanchez-Tapias JM, Rodes J. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002;36:986-92.
39. Donato F, Boffetta P, Puoti M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer 1998;75:347-54.
40. Kew MC. Hepatitis B and C viruses and hepatocellular carcinoma. Clin Lab Med 1996;16:395-406.
41. Wang XW, Gibson MK, Vermeulen W, Yeh H, Forrester K, Sturzbecher HW, Hoeijmakers JH, Harris CC. Abrogation of p53-induced apoptosis by the hepatitis B virus X gene. Cancer Res 1995;55:6012-6.
42. Tanaka H, Hiyama T, Tsukuma H, Okubo Y, Yamano H, Kitada A, Fujimoto I. Prevalence of second generation antibody to hepatitis C virus among voluntary blood donors in Osaka, Japan. Cancer Causes Control 1994;5:409-13.
43. Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, Nakanishi K, Fujimoto I, Inoue A, Yamazaki H, Kawashima T. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993;328:1797-801.
44. Tanaka H, Tsukuma H, Yamano H, Okubo Y, Inoue A, Kasahara A, Hayashi N. Hepatitis C virus Ib(II) infection and development of chronic hepatitis, liver cirrhosis and hepatocellular carcinoma: a case-control study in Japan. J Epidemiol 1998;8:244-9.
45. Imai Y, Tanaka H, Fukuda K, Zushi S, Yabuta T, Tujino A, Kurokawa M, Kono Y, Nishi K, Hayashi M. Present status of community-based HCV screening in Ikeda-Toyono region, Osaka prefecture, 2002. Acta Hepatol Jpn 2004;45:232-8.